Actively Recruiting
Study of MEN1703 Alone and With Glofitamab in Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Led by Ryvu Therapeutics SA · Updated on 2026-09-18
178
Participants Needed
35
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and anti-lymphoma activity of MEN1703 Dapolsertib hydrochloride, either alone or combined with glofitamab, in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. The study includes two groups one with patients who have not had anti-CD3xCD20 bispecific antibody therapy but have had at least two prior systemic treatments, and another with patients who have exhausted all standard treatment options. This is an open-label Phase 2 clinical trial with multiple study parts.
CONDITIONS
Brief Title
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
Research Team
H
Head of Clinical Operations
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here